AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 221 min read$PLXS

Keybanc upgrades Plexus to Overweight, sets $300 price target

Keybanc upgraded Plexus Corp to Overweight with a $300 price target, implying 18.9% upside from the Sep 21 close. The firm cites strong growth prospects in Aerospace/Defense and Industrial segments, with over 20% revenue growth expected in FY27, and disciplined capital deployment.

Original reporting
tradingview.com
Published Sep 22, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Keybanc upgrades Plexus to Overweight, sets $300 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$PLXSBullishMed
01

Why it matters

The upgrade could trigger re‑rating by other analysts and increase institutional interest.

02

Market read

First‑report upgrade provides actionable insight for traders focusing on mid‑cap industrial stocks.

03

What to watch

Potential supply‑chain constraints could temper revenue expansion.

Relevance 7/10Novelty 7/10Timing: today

Background

Keybanc's research note highlights strong growth prospects and disciplined capital deployment.

Company-level read

Ticker impact

$PLXSBullishHigh confidence
Context

Keybanc upgraded Plexus Corp to Overweight with a $300 price target, implying 18.9% upside.

Expected impact

Potential upside of ~15-20% as investors price in the new target.

Evidence & confidence

Upgrade and higher target are fresh primary disclosures that can drive buying pressure.

Market effects

Sector

Positive for aerospace/defense and industrial sectors as Plexus is a key supplier.

Regional

U.S. industrial equities may see modest lift.

Global

Limited to investors tracking mid‑cap industrial stocks.

Counterpoint

What could challenge this read

Upgrade may be premature if growth forecasts miss expectations.

Key entities

  • company
    Plexus Corp

    Industrial components manufacturer (ticker PLXS).

  • analyst
    Keybanc Capital Markets

    Investment bank providing the upgrade and price target.

Read at source← All news

Related articles

JUL 29
$PLXSHigh

PLEXUS CORP (PLXS): Results of Operations and Financial Condition

PLEXUS CORP (PLXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Plexus Announces Fiscal Third Quarter Financial Results NEENAH, WI – July 29, 2026 - Plexus Corp. (NASDAQ: PLXS) today announced financial results for our fiscal third quarter ended July 4, 2026, and guidance for our fiscal fourth quarter ending October 3, 2026. • Reports record

SEC EDGAR 8-K6 min
SEP 22
$EGOHigh

BofA upgrades Eldorado Gold stock rating on Skouries de-risking

BofA upgraded Eldorado Gold (EGO) to Buy with a $54 price target, citing confidence in the Skouries project and Olympias mine. The stock trades at $28.57, with Skouries seen as a key growth driver. Eldorado reported Q2 2026 revenue of $487M, up 7.7% YoY, and net earnings of $173M. Jefferies also initiated coverage with a Buy rating and $50 target.

investing.com2 min
SEP 22
$TSLAHighAI 8/10

Fitch Assigns Tesla First-Time 'BBB' IDR; Outlook Stable

Fitch Ratings assigned Tesla a 'BBB' IDR with a Stable Outlook, citing its strong BEV market position and AI investments. Tesla's profitability is expected to decline due to increased capex, likely turning FCF negative. The company plans to secure up to $30B in debt for investments, with leverage expected to rise. Tesla's unique business model and reliance on Elon Musk are key factors in its rating.

marketscreener.com2 min
SEP 22
$NVOLowAI 8/10

Why 2 promising heart drugs failed despite lowering risk factors

Novo Nordisk and Novartis reported failures in clinical trials for heart drugs targeting inflammation and lipoprotein A, despite the drugs effectively lowering these risk factors. Both drugs showed no better outcomes than placebos in preventing cardiovascular complications and deaths, suggesting these factors may be markers, not causes, of heart disease. The results may slow future drug development in this area.

oklahoman.com2 min